|
- SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention
- SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity
- "We are committed to improving public health through continuous innovation and global partnership."
INCHEON, South Korea, June 9, 2026 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that, after entering into a license agreement with the U.S. Centers for Disease Control and Prevention (CDC), it has initiated process development for an injectable rotavirus vaccine candidate. Following successful process development, the company plans to advance the vaccine through subsequent clinical trials, regulatory approval, and ultimately, commercialization.
Through the license agreement with CDC, SK bioscience has become the first Korean company to receive vaccine technology from the CDC. Previously, the CDC developed the injectable inactivated rotavirus vaccine technology and sponsored a Phase I clinical trial. SK bioscience plans to rapidly implement this technology domestically, establishing a production process that simultaneously enhances vaccine efficacy and reduces costs, while advancing through clinical development and ultimately commercialization.
The project is further supported by the Research Investment for Global Health Technology Foundation (the RIGHT Foundation). SK bioscience signed a research and development funding agreement with the RIGHT Foundation for the rotavirus vaccine process in June 2025.
The RIGHT Foundation is the first non-profit international public-private partnership funding agency in Korea, established through a three-way partnership between the Government of Korea, the Gates Foundation, and Korean life science companies. The foundation provides official development assistance (ODA) that supports essential R&D to reduce the infectious disease burden in low- and middle-income countries.
Rotavirus is a leading infectious disease that causes severe diarrhea and dehydration in children under five worldwide. According to Johns Hopkins University, approximately 24.4% of childhood deaths are due to diarrhea caused by rotavirus infection. With the introduction of rotavirus vaccines, infection rates have declined significantly in high-income countries, resulting in 99% of global rotavirus-related deaths being concentrated in low- and middle-income nations.
The introduction of oral rotavirus vaccines has significantly reduced infection rates in high-income countries, achieving over 85% vaccine effectiveness. However, in low- and middle-income countries, the vaccine effectiveness falls below 50% due to challenging environmental conditions and poor nutritional status. Consequently, these countries are turning their attention to injectable vaccines, which are expected to deliver stronger protective effects than oral formulations.
According to Business Research Insights, the global rotavirus vaccine market is expected to grow from USD 8.12 billion in 2024 to USD 13.9 billion by 2033, representing a CAGR of 6.2% due to increasing demand for rotavirus vaccines.
In addition, UNICEF's 2024 report shows that UNICEF procured a total of 329 million courses (2–3 doses per course) of rotavirus vaccines between 2011 and 2023. Most of these were supplied to Gavi-supported low-income countries. The procurement volume increased from 0.9 million doses in 2011 to 57 million courses for 57 countries in 2023, and demand from Gavi-supported countries is projected to reach approximately 64 million courses by 2028.
Jaeyong Ahn, CEO of SK bioscience, said, "We are pleased to collaborate with the CDC on the development of a rotavirus vaccine that has the potential to advance global public health. With the support of the RIGHT Foundation, we will continue to develop innovative vaccines to improve child health in low- and middle-income countries and fulfill our responsibility as a company contributing to a healthier future for people around the world."
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Tae-Gyun Kim (taegyunkim@sk.com)
- SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention
- SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity
- "We are committed to improving public health through continuous innovation and global partnership."
INCHEON, South Korea, June 9, 2026 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that, after entering into a license agreement with the U.S. Centers for Disease Control and Prevention (CDC), it has initiated process development for an injectable rotavirus vaccine candidate. Following successful process development, the company plans to advance the vaccine through subsequent clinical trials, regulatory approval, and ultimately, commercialization.
Through the license agreement with CDC, SK bioscience has become the first Korean company to receive vaccine technology from the CDC. Previously, the CDC developed the injectable inactivated rotavirus vaccine technology and sponsored a Phase I clinical trial. SK bioscience plans to rapidly implement this technology domestically, establishing a production process that simultaneously enhances vaccine efficacy and reduces costs, while advancing through clinical development and ultimately commercialization.
The project is further supported by the Research Investment for Global Health Technology Foundation (the RIGHT Foundation). SK bioscience signed a research and development funding agreement with the RIGHT Foundation for the rotavirus vaccine process in June 2025.
The RIGHT Foundation is the first non-profit international public-private partnership funding agency in Korea, established through a three-way partnership between the Government of Korea, the Gates Foundation, and Korean life science companies. The foundation provides official development assistance (ODA) that supports essential R&D to reduce the infectious disease burden in low- and middle-income countries.
Rotavirus is a leading infectious disease that causes severe diarrhea and dehydration in children under five worldwide. According to Johns Hopkins University, approximately 24.4% of childhood deaths are due to diarrhea caused by rotavirus infection. With the introduction of rotavirus vaccines, infection rates have declined significantly in high-income countries, resulting in 99% of global rotavirus-related deaths being concentrated in low- and middle-income nations.
The introduction of oral rotavirus vaccines has significantly reduced infection rates in high-income countries, achieving over 85% vaccine effectiveness. However, in low- and middle-income countries, the vaccine effectiveness falls below 50% due to challenging environmental conditions and poor nutritional status. Consequently, these countries are turning their attention to injectable vaccines, which are expected to deliver stronger protective effects than oral formulations.
According to Business Research Insights, the global rotavirus vaccine market is expected to grow from USD 8.12 billion in 2024 to USD 13.9 billion by 2033, representing a CAGR of 6.2% due to increasing demand for rotavirus vaccines.
In addition, UNICEF's 2024 report shows that UNICEF procured a total of 329 million courses (2–3 doses per course) of rotavirus vaccines between 2011 and 2023. Most of these were supplied to Gavi-supported low-income countries. The procurement volume increased from 0.9 million doses in 2011 to 57 million courses for 57 countries in 2023, and demand from Gavi-supported countries is projected to reach approximately 64 million courses by 2028.
Jaeyong Ahn, CEO of SK bioscience, said, "We are pleased to collaborate with the CDC on the development of a rotavirus vaccine that has the potential to advance global public health. With the support of the RIGHT Foundation, we will continue to develop innovative vaccines to improve child health in low- and middle-income countries and fulfill our responsibility as a company contributing to a healthier future for people around the world."
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Tae-Gyun Kim (taegyunkim@sk.com)
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development
|
DUBAI, UAE, June 9, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is making stock CFD trading completely free via Bybit TradFi from now until July 10, 2026. For a limited time, users can access over 380 global stock CFDs with zero commissions and zero swap fees on Bybit TradFi: no hidden layers, no workarounds, and with up to $100,000 in total rebates.
The event offers a truly free experience for Bybit TradFi users, and comes at a time when Bybit is launching a dedicated RWA (real-world assets) portal that unifies all of its RWA and RWA-adjacent offerings: from tokenized equities and precious metals on Bybit Spot, to comprehensive stock CFD trading through Bybit TradFi, to traditional financial asset perpetual contracts, and RWA yield products on Bybit Earn.
Through the initiative, Bybit TradFi is the only avenue of its kind among mainstream CEXs to waive commissions and swap fees simultaneously. Traders now experience true cost-efficient global market access all from a unified USDT-denominated account on Bybit.
Zero Swap Fees: Global Market Access at No Costs
The zero-fee event for premium stock CFD trading offers traders exceptional access to Bybit TradFi with genuine cost efficiency. Not just free on paper, but also with hidden and standard costs of trading removed:
- Zero Commission + Zero Swap Fee: Truly frictionless trading at no fee; users can select the Zero-Fee Mode with pure Straight Through Processing (STP) pricing with no hidden fee structures. Traders can earn up to 2,000 USDT in Swap Fee rebates.
- 380+ Global Stock CFDs: CFD trading for leading technology stocks (NVIDIA, Apple, Tesla, Microsoft, Google), commodities (gold, oil), forex pairs, and market indices - all from a single USDT-denominated account
- Up to 5x Leverage: Strategic capital deployment with flexible leverage options designed for different trading styles
The Complete Bybit RWA Ecosystem
The launch marks Bybit's commitment to democratizing access to both crypto and RWA within a single, integrated platform. The new Bybit RWA Portal consolidates all forms of RWA exposure available on Bybit:
- Bybit TradFi (Stock CFD Trading): Over 300 global stock CFDs with zero swap fees, 5x leverage, and USDT settlement. The flagship product line for TradFi asset exposure also covers forex, global indices, commodities, oil, and precious metals.
- xStocks (Tokenized Equities): Trading tokenized and fractional shares of global companies on Bybit Spot, achieving on-chain ownership without custody complexity
- Tokenized Precious Metals: Trading tokenized gold, silver and other precious metals on Bybit Spot with instant settlement
- TradFi Asset Perpetual Contracts: Accessing leveraged exposure to trending U.S. equities, ETF, and commodity baskets through perpetuals
- Bybit Earn (RWA Yields): Earning yield on RWA holdings through Bybit Earn, bridging passive income with digital finance
Bybit's unified approach to RWA's on-chain evolution allows traders and investors to choose their preferred access method: perpetuals for leverage and short selling, spot for tokenized ownership, or Earn products for passive income, all without switching platforms or managing multiple accounts.
In the past two years, engagement with TradFi's deep global markets among crypto-native traders has grown meaningfully. The change is unfolding as digital asset portfolios mature and diversification becomes part of sound portfolio strategy. Pioneering in TradFi exposure, Bybit was the first centralized crypto exchange to introduce traditional asset CFD trading in as early as 2022.
Terms and conditions apply. For details of participation rules and eligibility, users may visit: Trade Stock CFDs with 0 swap fees on Bybit TradFi
Disclaimer: Bybit TradFi is powered by Infra Capital (Mauritius FSC licensed). The service is now available to eligible users through the official Bybit app and website. Bybit TradFi is not available to residents of the European Economic Area, among other restrictions. For details of regional limitations, terms and conditions, and user eligibility, users may visit Bybit TradFi. Trading comes with risk.
#Bybit / #NewFinancialPlatform
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, June 9, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is making stock CFD trading completely free via Bybit TradFi from now until July 10, 2026. For a limited time, users can access over 380 global stock CFDs with zero commissions and zero swap fees on Bybit TradFi: no hidden layers, no workarounds, and with up to $100,000 in total rebates.
The event offers a truly free experience for Bybit TradFi users, and comes at a time when Bybit is launching a dedicated RWA (real-world assets) portal that unifies all of its RWA and RWA-adjacent offerings: from tokenized equities and precious metals on Bybit Spot, to comprehensive stock CFD trading through Bybit TradFi, to traditional financial asset perpetual contracts, and RWA yield products on Bybit Earn.
Through the initiative, Bybit TradFi is the only avenue of its kind among mainstream CEXs to waive commissions and swap fees simultaneously. Traders now experience true cost-efficient global market access all from a unified USDT-denominated account on Bybit.
Zero Swap Fees: Global Market Access at No Costs
The zero-fee event for premium stock CFD trading offers traders exceptional access to Bybit TradFi with genuine cost efficiency. Not just free on paper, but also with hidden and standard costs of trading removed:
- Zero Commission + Zero Swap Fee: Truly frictionless trading at no fee; users can select the Zero-Fee Mode with pure Straight Through Processing (STP) pricing with no hidden fee structures. Traders can earn up to 2,000 USDT in Swap Fee rebates.
- 380+ Global Stock CFDs: CFD trading for leading technology stocks (NVIDIA, Apple, Tesla, Microsoft, Google), commodities (gold, oil), forex pairs, and market indices - all from a single USDT-denominated account
- Up to 5x Leverage: Strategic capital deployment with flexible leverage options designed for different trading styles
The Complete Bybit RWA Ecosystem
The launch marks Bybit's commitment to democratizing access to both crypto and RWA within a single, integrated platform. The new Bybit RWA Portal consolidates all forms of RWA exposure available on Bybit:
- Bybit TradFi (Stock CFD Trading): Over 300 global stock CFDs with zero swap fees, 5x leverage, and USDT settlement. The flagship product line for TradFi asset exposure also covers forex, global indices, commodities, oil, and precious metals.
- xStocks (Tokenized Equities): Trading tokenized and fractional shares of global companies on Bybit Spot, achieving on-chain ownership without custody complexity
- Tokenized Precious Metals: Trading tokenized gold, silver and other precious metals on Bybit Spot with instant settlement
- TradFi Asset Perpetual Contracts: Accessing leveraged exposure to trending U.S. equities, ETF, and commodity baskets through perpetuals
- Bybit Earn (RWA Yields): Earning yield on RWA holdings through Bybit Earn, bridging passive income with digital finance
Bybit's unified approach to RWA's on-chain evolution allows traders and investors to choose their preferred access method: perpetuals for leverage and short selling, spot for tokenized ownership, or Earn products for passive income, all without switching platforms or managing multiple accounts.
In the past two years, engagement with TradFi's deep global markets among crypto-native traders has grown meaningfully. The change is unfolding as digital asset portfolios mature and diversification becomes part of sound portfolio strategy. Pioneering in TradFi exposure, Bybit was the first centralized crypto exchange to introduce traditional asset CFD trading in as early as 2022.
Terms and conditions apply. For details of participation rules and eligibility, users may visit: Trade Stock CFDs with 0 swap fees on Bybit TradFi
Disclaimer: Bybit TradFi is powered by Infra Capital (Mauritius FSC licensed). The service is now available to eligible users through the official Bybit app and website. Bybit TradFi is not available to residents of the European Economic Area, among other restrictions. For details of regional limitations, terms and conditions, and user eligibility, users may visit Bybit TradFi. Trading comes with risk.
#Bybit / #NewFinancialPlatform
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Bybit TradFi Doubles Down on Zero-Fee Stock CFD Trading: 0 Commission + 0 Swap Fee
